Early effects of LT3 + LT4 combination therapy on quality of life in hypothyroid patients: a randomized, double-blind, parallel-group comparison trial

Table 2 Comparison in changes of clinical and biochemical variables at baseline and 6 months

	LT4 + Placebo			LT4 + LT3			Between-group comparison
	Baseline	6 months	p-value†	Baseline	6 months	p-value†	Difference (95% CI)^a	p-value*
Weight, kg	72.10 ± 14.0	72.10 ± 13.91	1.0	75.85 ± 12.8	75.97 ± 12.26	0.65	0.13 (-0.51, 0.76)	0.69
SBP, mmHg	114.4 ± 14.4	113.63 ± 12.13	0.38	114.8 ± 13.8	114.64 ± 13.60	0.91	0.59 (-2.5, 3.7)	0.71
DBP, mmHg	71.7 ± 10.0	70.9 ± 8.0	0.39	75.3 ± 7.8	74.6 ± 7.2	0.53	0.12 (-2.71, 2.95)	0.93
TSH, mU/L	2(1.4–2.9)	2(1.31–2.67)	0.06	2.4(1.4–3.3)	1.80(1.10–3.20)	0.02	0.14 (-0.12, 0.41)	0.29
Physical activity, Met-min/week	132.0(33.0–240.0)	132.0(33.0–237.0)	0.02	89.0(33.0–175.0)	90.0 (33.0–183.0)	0.11	0.0 (0.0–0.0)	0.96

Values are mean ± SD for normally distributed, median (Q1-Q3) for skewed continuous variables, and n (%) for categorical variables were reported
SBP systolic blood pressure, DBP diastolic blood pressure, TSH thyroid-stimulating hormone, CI confidence interval
^aMean and median difference between treatment groups, as appropriate
^† p-values compare the changes from the baseline within each treatment group using paired t-test or Wilcoxon signed-rank test as appropriate
^* p-values compare the changes from the baseline between two treatment groups using an independent t-test or Mann–Whitney U Test as appropriate

ISSN: 1472-6823